Verona Pharma plc / Fundamentals
Income statement
- Net revenue
€190.20M - Cost of goods sold
€9.22M - Gross profit
€180.98M - SG&A expenses
€190.06M - R&D expenses
€38.98M - EBITDA
-€89.08M - D&A
€958.27K - EBIT
-€48.06M - Interest expenses
€14.45M - EBT
-€62.59M - Tax expenses
€7.07M - Net income
-€69.66M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€12.41M - Changes in working capital
-€61.97M - Operating cash flow
-€62.19M - Capex
€420.41K - Other investing cash flow
-€497.64K - Net investing cash flow
-€918.05K - Total cash dividends paid
€0.00 - Issuance of common stock
€86.82M - Debt repayment
-€85.80M - Other financing cash flow
€89.48M - Net financing cash flow
€90.49M - Foreign exchange effects
€1.29M - Net change in cash
€28.67M - Cash at end of period
€375.82M - Free cash flow
-€61.77M
Balance sheet
- Cash and cash equivalents
€375.82M - Cash and short-term investments
€375.82M - Total receivables
€74.58M - Inventory
€7.39M - Other current assets
€13.13M - Total current assets
€470.91M - Property, plant & equipment
€2.20M - Goodwill
€467.61K - Intangible assets
€0.00 - Long-term investments
€12.87M - Other non-current assets
€5.07M - Total non-current assets
€20.61M - Total assets
€491.52M - Accounts payable
€2.95M - Short-term debt
€870.01K - Other current liabilities
€40.15M - Total current liabilities
€43.96M - Long-term debt
€208.80M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€208.80M - Total liabilities
€252.77M - Common stock
€38.63M - Retained earnings
-€486.57M - Other equity
-€3.95M - Total equity
€238.76M - Total liabilities and shareholders' equity
€491.52M
Company information
- Market capitalization
€6.80B - Employees
209 - Enterprise Value
€7.29B
Company ratios
- Gross margin
-
95.2% Much better than peer group: -27,482.1% - EBITDA margin
-
-46.8% Much better than peer group: -41,725.1% - EBIT margin
-
-25.3% Much better than peer group: -42,266.8% - EBT margin
-
-32.9% Much better than peer group: -42,721.5% - Net margin
-
-36.6% Much better than peer group: -42,126.4% - ROE
-
-29.2% Better than peer group: -43.8% - ROA
-
-14.2% Much better than peer group: -72.9% - Asset turnover
-
38.7% Much better than peer group: 9.0% - FCF margin
-
-32.9% Much better than peer group: -37,571.6% - FCF yield
-0.9% - Efficiency ratio
146.8% - Net sales per employee
-
€910.03K - Net income per employee
-
-€333.29K